Table 2.
Drug resistance detection according to the method of interrupting an NNRTI
| Patients who interrupted efavirenz | Patients who interrupted nevirapine | ||||||
|---|---|---|---|---|---|---|---|
| All patients who stopped an NNRTI* N=141 | Simultaneous-interruption N=29 | Staggered-interruption N=45 | Switched-interruption N=13 | Simultaneous-interruption N=31 | Staggered-interruption N=11 | Switched-interruption N=11 | |
| Follow-up resistance mutations (N, %): | |||||||
| NRTI mutations | 23 (16.3%) | 6 (20.7%) | 9 (20.0%) | 1 (7.7%) | 2 (6.5%) | 2 (18.2%) | 2 (18.2%) |
| NNRTI mutations | 18 (12.8%) | 5 (17.2%) | 6 (13.3%) | 0 (0.0%) | 5 (16.1%) | 1 (9.1%) | 1 (9.1%) |
| PI mutations | 11 (7.8%) | 2 (6.9%) | 4 (8.9%) | 1 (7.7%) | 0 (0.0%) | 2 (18.2%) | 1 (9.1%) |
| Follow-up resistance mutations (N, %): | 39 (27.7%) | 9 (31.0%) | 15 (33.3%) | 1 (7.7%) | 6 (19.3%) | 4 (36.4%) | 3 (17.3%) |
| NRTI mutations (N, %): | |||||||
| 41L | 6 (4.3%) | 0 (0.0%) | 4 (8.9%) | 0 (0.0%) | 2 (6.5%) | 0 (0.0%) | 0 (0.0%) |
| 62V | 2 (1.4%) | 1 (3.5%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
| 65R | 1 (0.7%) | 1 (3.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 67N | 6 (4.3%) | 2 (6.9%) | 2 (4.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) |
| 69 insertion | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
| 70R | 8 (5.7%) | 1 (3.5%) | 3 (6.7%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 2 (18.2%) |
| 74V | 2 (1.4%) | 1 (3.5%) | 0 (0.0%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
| 75I | 1 (0.7%) | 1 (3.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 116Y | 1 (0.7%) | 0 (0.0%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 151M | 1 (0.7%) | 0 (0.0%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 184I/V | 13 (9.2%) | 2 (6.9%) | 4 (8.9%) | 1 (7.7%) | 2 (6.5%) | 1 (9.1%) | 2 (18.2%) |
| 210W | 5 (3.6%) | 0 (0.0%) | 3 (6.7%) | 0 (0.0%) | 1 (3.2%) | 1 (9.1%) | 0 (0.0%) |
| 215Y/F | 9 (6.4%) | 1 (3.5%) | 4 (8.9%) | 0 (0.0%) | 1 (3.2%) | 1 (9.1%) | 2 (18.2%) |
| 219Q/E | 5 (3.6%) | 1 (3.5%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 1 (9.1%) |
| NNRTI mutations (N, %): | |||||||
| 103N | 5 (3.6%) | 2 (6.9%) | 3 (6.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 108I | 5 (3.6%) | 0 (0.0%) | 3 (6.7%) | 0 (0.0%) | 1 (3.2%) | 0 (0.0%) | 1 (9.1%) |
| 181C/I | 2 (1.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (6.5%) | 0 (0.0%) | 0 (0.0%) |
| 188C/H/L | 4 (2.8%) | 3 (10.3%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 190S/A | 4 (2.8%) | 1 (3.5%) | 0 (0.0%) | 0 (0.0%) | 2 (6.5%) | 1 (9.1%) | 0 (0.0%) |
| PI mutations (N, %): | |||||||
| 30N | 3 (2.1%) | 1 (3.5%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) |
| 46I/L | 4 (2.8%) | 0 (0.0%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 1 (9.1%) |
| 54M/L | 1 (0.7%) | 0 (0.0%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 82A/F/L/T/S | 1 (0.7%) | 0 (0.0%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 84V | 2 (1.4%) | 1 (3.5%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 90M | 3 (2.1%) | 1 (3.5%) | 0 (0.0%) | 1 (7.7%) | 1 (3.2%) | 0 (0.0%) | 0 (0.0%) |
*
NB: In one patient who interrupted a delarvidine containing regimen the following mutations were detected: RT: 67N, 70R, 184I/V, 219Q/E, PRO: 50L/V
Any IAS-USA mutation that is not listed in the above table was not seen in the predominant virus of patients in our comparisons (i.e. NRTI: 77L, 115F; NNRTI: 100I, 106A/M, 225H, 236L; and PI: 32I, 33F, 47V/A, 48V, 76V, 88S).